Thursday, 3 April 2025
24.9 C
Singapore
26.8 C
Thailand
20.7 C
Indonesia
27 C
Philippines

Bioptimus secures US$41M to create groundbreaking AI for biology

French startup Bioptimus raises US$41M to develop AI that simulates biological processes, driving medical, biotech, and cosmetic innovations.

A French AI startup, Bioptimus, has raised US$41 million to develop an innovative foundational AI model explicitly designed for biology. This cutting-edge technology aims to simulate biological processes and drive medical, pharmaceutical, and even cosmetic discoveries.

A new era of biology

Just as OpenAIโ€™s ChatGPT revolutionised text-based interactions, Bioptimus plans to transform the understanding of biology by creating a model capable of simulating biological systems. The model will leverage raw data from molecules to entire organisms, enabling scientists to predict disease outcomes and develop more effective treatments.

Jean-Philippe Vert, co-founder and CEO of Bioptimus, describes the technology as โ€œthe GPT of biologyโ€ but with a focus on biological simulations instead of text generation. This approach could redefine how researchers analyse and interpret biological data, pushing the boundaries of science in unprecedented ways.

โ€œEssentially, itโ€™s like the GPT of biology โ€” but instead of generating text, weโ€™re simulating biology,โ€ Vert explained.

Franceโ€™s rise as an AI powerhouse

France is quickly becoming a hub for AI innovation. Over the past 18 months, several generative AI startups, including Mistral AI, Hugging Face, and H, have secured significant investments. Bioptimus, founded just last year, has already raised US$76 million in total funding, including a US$35 million seed round shortly after its launch.

Bioptimus benefits from the expertise of its six co-founders, such as Rodolphe Jenatton, who previously worked as a senior research scientist at Amazon and Google. Vert himself is the chief R&D officer at Owkin, another French AI-focused biotech unicorn. Owkin, a pioneer in using AI for drug discovery, has amassed a wealth of multimodal patient data, which Bioptimus is now utilising to train its foundational model.

Rather than embedding the foundational model development within Owkin, the team created Bioptimus as an independent entity. This approach allows for a focused effort on building large-scale foundational models while maintaining flexibility in securing resources like data and computing power.

Expanding horizons

Since its inception, Bioptimus has launched H-Optimus-0, an open-source foundation model for pathology, trained on millions of images to advance disease diagnosis and research, including cancer. With its latest funding, the company plans to enhance its AI platform using a broader range of data sources and develop partnerships with pharmaceutical and biotech companies.

A multi-modal foundation model, set to launch later this year, will span the entire biological spectrum and offer applications across various industries. Vert believes the model will pave the way for breakthroughs beyond healthcare, unlocking biological discoveries in unimaginable ways.

โ€œBeyond pharmaceuticals, this model will unlock limitless possibilities across many other industries, driving biological discoveries in ways we are only beginning to imagine,โ€ Vert noted.

The US$41 million funding round was led by Cathay Innovation, a U.S.-based company, with contributions from Sofinnova Partners, Bpifrance, Andera Partners, Hitachi Ventures, and others. This injection of capital solidifies Bioptimusโ€™s position as a frontrunner in developing AI tools for biology.

Hot this week

Nvidia in talks to acquire AI server rental company Lepton AI

Nvidia is reportedly in talks to acquire Lepton AI in a deal worth several hundred million dollars, expanding into AI-powered server rentals.

Mobvistaโ€™s XMP and AdsPolar recognised as Meta AdTech Business Partners

Mobvistaโ€™s XMP and AdsPolar gain Meta AdTech Partner status, giving users early access to tools, insights, and expert campaign support.

Chinese investor questions commercial future of humanoid robots

Chinese venture capitalist Allen Zhu questions the commercial potential of humanoid robots, sparking debate amid rising AI investment in China.

OpenAI pauses free GPT-4o image generation after viral Studio Ghibli trend

OpenAI halts free GPT-4o image generation after viral Studio Ghibli trend raises legal concerns, leaving paid users with continued access.

Samsung Galaxy A06 5G offers modern features at an affordable S$228

The Samsung Galaxy A06 5G, with a 50MP camera and 5,000mAh battery, launches in Singapore on March 21, 2025, for S$228.

Qualcomm expands AI research with MovianAI acquisition

Qualcomm has acquired Vietnamese AI research firm MovianAI to boost its AI development in smartphones, PCs, and software-defined vehicles.

Roblox introduces new parental controls to enhance child safety

Roblox introduces new parental controls, allowing parents to block games, restrict friends, and monitor their childโ€™s activity for better safety.

Anthropic introduces Claude for Education, a new AI chatbot plan for universities

Anthropic launches Claude for Education, an AI chatbot plan for universities that offers advanced learning tools and administration support.

Exabeam introduces Nova, an agentic AI that boosts cybersecurity operations

Exabeam unveils Nova, a proactive AI agent that boosts security team productivity and reduces incident investigation time by over 50%.

Related Articles